
0:00
22:28
On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr. Jake Chen.
Otros episodios de "Drug Discovery AI Talk"



No te pierdas ningún episodio de “Drug Discovery AI Talk”. Síguelo en la aplicación gratuita de GetPodcast.








